Abstract
The selective serotonin reuptake inhibitor (SSRI) fluvoxamine could reduce the need for hospitalisation in high-risk patients with early diagnosed COVID-19, a Brazilian study has shown. The randomised study, published in The Lancet Global Health on 27 October 2021, found an absolute risk reduction of 5%, and a relative risk reduction of 32%, in hospitalisation for […]
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
